ipratropium + fenoterol




Concise Prescribing Info
Per actuation Ipratropium Br 20 mcg, fenoterol HBr 50 mcg
Maintenance treatment of reversible bronchospasm in bronchial asthma, COPD, chronic bronchitis & pulmonary emphysema.
Dosage/Direction for Use
Acute asthma attack Adult & childn >6 yr Initially 2 inhalations. Patients who require additional symptomatic control 2 more inhalations may be taken after 5 min away from the 1st inhalations. If the patient needs >4 inhalations, or the patient develops a significant decrease in lung function, this may be a marker of destabilization of disease. Patient requires immediate reassessment of treatment regimen. Intermittent & long-term treatment Adult & childn >6 yr 1-2 inhalations. Max: 8 inhalations daily.
Hypersensitivity to ipratropium Br, fenoterol HBr or atropine-like substances. Hypertrophic obstructive cardiomyopathy & tachycardia.
Special Precautions
If paradoxical bronchospam occurs, discontinue treatment & consider other treatment. Patients w/ narrow-angle glaucoma, prostatic hyperplasia, or bladder-neck obstruction, particularly if receiving an anticholinergic by another route; DM, ischemic heart disease or recent MI, severe organic heart or vascular disorders, arrhythmia or severe heart failure, hyperthyroidism, phaeochromocytoma. Hypokalemia. Deterioration of asthma control w/ increasing use of bronchodilators. Concomitant use w/ other sympathomimetic bronchodilators. May affect the ability to drive & use machines. Pregnancy & lactation. Childn. Elderly.
Adverse Reactions
Cough, dry mouth, headache, tremor, pharyngitis, nausea, dizziness, dysphonia, tachycardia, palpitations, vomiting, increased systolic BP, nervousness.
Drug Interactions
May enhance pharmacological effect & adverse reactions w/ other β-agonist, anticholinergics & xanthine derivatives. Potentially serious reduction in bronchodilation w/ ophth & systemic β-adrenergic blockers. Increased induced hypokalemia w/ corticosteroids, non-K sparing diuretics, or methylxanthines & other xanthine derivatives. Increased susceptibility to arrhythmias by digoxin. Action on vascular system may be potentiated w/ MAOIs & TCAs. Increased CV adverse effects w/ halogenated hydrocarbon anaesth (eg, halothane, trichloroethylene & enflurane). May decrease conc of serum K.
MIMS Class
Antiasthmatic & COPD Preparations
ATC Classification
R03AL01 - fenoterol and ipratropium bromide ; Belongs to the class of combination of adrenergics with anticholinergics, that may also include a corticosteroid. Used in the treatment of obstructive airway diseases.
Aerobidol MDI
(CFC-free) 200 dose x 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in